Cardiac
According to the haemostatic agent’s review1 article, an ideal haemostatic agent would achieve haemostasis and show other potential benefits including:
“better visualization of the surgical area, shorter operative times, decreased requirement for transfusions, better management of an anticoagulated patient, decreased wound healing time and overall improvement in patient recovery time”.
Based on self-assembling peptide technology, 3-D Matrix has obtained CE mark approval for the surgical haemostatic agents, PuraBond and PuraStat, which have multiple unique features that distinguish it from competitors and make it highly suitable for cardiac surgery.
According to the haemostatic agent’s review1 article, an ideal haemostatic agent would achieve haemostasis and show other potential benefits including:
“better visualization of the surgical area, shorter operative times, decreased requirement for transfusions, better management of an anticoagulated patient, decreased wound healing time and overall improvement in patient recovery time”.
Based on self-assembling peptide technology, 3-D Matrix has obtained CE mark approval for the surgical haemostatic agent, PuraBond, which has multiple unique features that distinguish it from competitors and make it highly suitable for cardiac surgery.
According to the haemostatic agent’s review1 article, an ideal haemostatic agent would achieve haemostasis and show other potential benefits including:
“better visualization of the surgical area, shorter operative times, decreased requirement for transfusions, better management of an anticoagulated patient, decreased wound healing time and overall improvement in patient recovery time”.
Based on self-assembling peptide technology, 3-D Matrix has obtained CE mark approval for the surgical haemostatic agent, PuraStat, which has multiple unique features that distinguish it from competitors and make it highly suitable for cardiac surgery.
Product Features
Please note: PuraBond and PuraStat are only available within some regions in the country. Please check its availability with your local representative or contact 3-D Matrix for more information.
PuraBond and PuraStat are both part of the RADA16 family. Please read carefully the instructions for use, indications and contraindications of the products.3,4
PuraBond and PuraStat are both part of the RADA16 family. Please read carefully the instructions for use, indications and contraindications of the product.3
Please read carefully the instructions for use, indications and contraindications of the product.3
PuraBond is suitable for:
PuraStat/PuraBond is suitable for:
PuraStat is suitable for:
Read our case reports
Join us with the international experts:
1. Comparison of hemostatic agents used in vascular surgery; Krishna S. Vyas, Sibu P. Saha; Expert Opin Biol Ther. 2013 December; 13(12): 1663–1672.
2. Data on file (Swell Report 2018, Eun Seok Gil 12/06/2018)
3. PuraStat IFU-007 Rev 2
4. PuraBond IFU-009 Rev 2
1. Comparison of hemostatic agents used in vascular surgery; Krishna S. Vyas, Sibu P. Saha; Expert Opin Biol Ther. 2013 December; 13(12): 1663–1672.
2. Data on file (Swell Report 2018, Eun Seok Gil 12/06/2018)
3. PuraStat IFU-007 Rev 2
2. Data on file (Swell Report 2018, Eun Seok Gil 12/06/2018)
3. PuraStat IFU-007 Rev 2
4. PuraBond IFU-009 Rev 2
Medical Specialities
